DOCSLIB.ORG

Antagonism of Histamine-Activated Adenylate Cyclase in Brain by D

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antagonism of Histamine-Activated Adenylate Cyclase in Brain by D Proc. Natl. Acad. Sci. USA Vol.74, No. 12, pp. 5697-5701, December 1977 Medical Sciences Antagonism of histamine-activated adenylate cyclase in brain by D-lysergic acid diethylamide (histaminergic antagonists/adenosine 3':5'-cyclic monophosphate/H2-receptors/ergots/D-2-bromolysergic acid diethylamide) JACK PETER GREEN, CARL LYNN JOHNSON, HAREL WEINSTEIN, AND SAUL MAAYANI Department of Pharmacology, Mount Sinai School of Medicine of the City University of New York, 100th Street and Fifth Avenue, New York, New- York 10029 Communicated by Vincent P. Dole, August 19, 1977 ABSTRACT D-Lysergic acid diethylamide and D-2-bro- (ED50; amount necessary to produce half-maximal response) molysergic acid diethylamide are competitive antagonists of and antagonist affinities (pA2) were not altered. the histamine activation of adenylate cyclase [ATP pyrophos- Adenylate Cyclase Assay. The assay system has been de- phate-lyase (cyclizing); E.C. 4.6.1.11 in broken cell preparations in All additions of the hippocampus and cortex of guinea pig brain. The ade- scribed (8). All assays were performed triplicate. nylate cyclase is linked to the histamine H2-receptor. Both D- were made to the assay tubes on ice. They were then transferred lysergic acid diethylamide and D-2-bromolysergic acid dieth- to a 30° shaking incubator and preincubated for 5 min to allow ylamide show topological congruency with potent H2-antago- the enzymatic activity to reach a steady state and to eliminate nists. D-2-Bromolysergic acid diethylamide is 10 times more the influence of any lag periods in hormone activation. After potent as an H2-antagonist than cimetidine, which has been the the preincubation period, 25 of [a-32PJATP (1-2 gCi) were most potent H2-antagonist reported, and D-lysergic acid di- pl ethylamide is about equipotent to cimetidine. Blockade of added and in most cases the reaction was allowed to proceed H2-receptors could contribute to the behavioral effects of D-2- for 10 min, when it was stopped by adding 100 ,il of 1% sodium bromolysergic acid diethylamide and D-lysergic acid dieth- dodecyl sulfate. After addition of 650 gl of [3H]cyclic AMP ylamide. (13H]cAMP; 5000-10,000 cpm) to monitor recovery, the labeled cAMP was isolated with an alumina and Dowex column (9). Evidence is growing that histamine may function as a neuro- The reaction was linear with protein concentration (10) in the transmitter (see reviews, refs. 1-4). Histamine has a nonuniform range used and for at least 15 min after addition of the [a- regional distribution in brain. Most of the histamine is found 32pJATP. in subcellular fractions containing nerve endings. Brain contains Treatment of the Data. Curve fitting techniques (11) were specific enzymes for histamine formation and metabolism. used to estimate the apparent ED50 values, maximum stimu- Histamine appears to turn over rapidly. Potassium ions release lation by agonists, and parallelism of the dose-response curves. histamine from brain slices by a calcium-dependent process. Antagonism was analyzed by Schild plots (12) in which an- Brain lesions result in a fall in the activity of histidine decar- tagonism is expressed by the dose-ratios .(DR) of agonist needed boxylase in areas distal to the lesion. Neurons respond to his- to produce half-maximal responses in the presence and absence tamine. Histamine stimulates the activity of adenylate cyclase of different concentrations of antagonists (B). Simple compet- JATP pyrophosphate-lyase (cyclizing); EC 4.6.1.1] and this itive antagonism results in a straight line of slope 1 when log effect is blocked by histamine HI-antagonists (5, 6) and hista- (DR - 1) is plotted against log B; and the intercept with the mine H2-antagonists (6, 7). We show here that D-lysergic acid abscissa is -log KB, where KB is the apparent dissociation diethylamide (D-LSD) and D-2-bromo-LSD (D-BrLSD) are constant for the antagonist-receptor interaction; -log KB is competitive antagonists of histamine in the activation of the referred to as pA2. H2-receptor linked to adenylate cyclase in the hippocampus arid cortex of the brain. RESULTS MATERIALS AND METHODS Histamine Receptor Linked to Adenylate Cyclase. Hista- Preparation of Tissue. Membrane-bound adenylate cyclase mine stimulated adenylate cyclase activity in all areas of the was prepared from brain by homogenization in a Potter-El- guinea pig brain that were examined-cortex, hippocampus, vejhem glass-Teflon vessel in 0.32 M sucrose/5 mM Tris-HCl/1 thalamus, striatum, hypothalamus, and central grey; cortex and mM ethylene glycol bis(3-aminoethyl ether)-N,N'-tetraacetate hippocampus were more sensitive than the other regions, as (EGTA)/1 mM dithiothreitol pH 7.4. The homogenate was shown by others (7). Rat hippocampal adenylate cyclase was centrifuged at 1000 X g and the supernatant fraction was also stimulated by histamine (Table 1), but it was less sensitive centrifuged again at 27,000 X g. The pellet from the second to histamine than guinea pig hippocampal adenylate cy- centrifugation was washed twice by resuspension in the same clase. medium and collected by centrifugation. The final pellet was The ED50 values for histamine, dimaprit, 4-methylhistamine, suspended in the same medium at a protein concentration of 2-methylhistamine, and N't,N't-dimethylhistamine were 14 0.5-0.7 mg/mi. The membranes could be quickly frozen with + 1, 6.4 + 0.45, 24, 120, and 21 + 2.3 MM, respectively. Previous dry ice/acetone and stored at -70°. Freezing and storage in- studies of histamine, 4-methylhistamine, and 2-methylhista- variably resulted in an increase in basal activity and a decrease mine on adenylate cyclase activity in broken cell preparations in maximal histamine activation, but the agonist potencies of the guinea pig hippocampus yielded similar ED50 values (7). It is especially noteworthy that dimaprit, a compound with The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked Abbreviations: D-LSD, D-lysergic acid diethylamide; BrLSD, D-2- "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate bromo-LSD; cAMP, cyclic AMP; ED50, amount of agonist necessary this fact. to produce half-maximal response. 5697 Downloaded by guest on September 28, 2021 5698 Medical Sciences: Green et al. Proc. Natl. Acad. Sci. USA -74 (1977' Table 1. Effect of histamine on rat hippocampal adenylate 90 cyclase activity % increase in activity (±SEM) at Animal histamine concentration no. Basal* 10-5 M l0-4 M 10-3 M 1 21.5 + 0.2 13.8 + 2.4t 29.4 ± 1.4t 39.7 ± 2.2t 2 19.6 ± 0.4 9.5 + 0.31 27.6 ± 0.3t 37.8 ± 1.It 3 19.4 + 0.2 14.6 ± 1.41 33.7 ± 2.2t 42.4 i 0.5t * The amount of homogenate protein was 193, 187, and 191 ug, re- spectively, for the three animals. Activity is expressed as pmol of cAMP formed/min per mg of protein (±SEM). t Significantly different (P < 0.001) from basal activity. I lo-3 Significantly different (P < 0.05) from basal activity. Histamine, M considerable H2-agonist activity but with less than 0.0001% of the activity of histamine on HI-receptors (13), was active in the same concentration range as was histamine. Although measuring the relative potencies of agonists has V- been useful in classifying histamine receptors (14), these mea- 0*I1.0 surements are not dependable tools: the potencies of dimaprit and other agonists (13, 15) can vary 50-fold relative to histamine on different H2-receptors. More persuasive evidence for de- ~0 fining receptors comes from studies of antagonists (14). Fig. 1 shows typical dose-response curves for the effect of histamine on guinea pig hippocampal adenylate cyclase activity in the presence and absence of different concentrations of the H2- antagonist, cimetidine. Cimetidine caused a parallel shift in the -6.5 -6.0 -5.5 -5.0 -4.5 dose-response curve. Also shown in Fig. 1 is the Schild plot for log[cimetidine], M cimetidine with histamine or dimaprit as agonists. The fact that of the the dose-response curves of both histamine and the H2-selective FIG. 1. (Upper) Increase in adenylate cyclase activity guinea pig hippocampus with varying concentrations of histamine dimaprit are shifted to the same degree by cimetidine clearly in the absence and presence of cimetidine. Each point is the mean of were H2- establishes that both agonists reacting solely with triplicate determinations. Cimetidine alone did not affect basal ac- receptors linked to adenylate cyclase. The slope of the Schild tivity, which was 79.6 + 1.1 pmol/min per mg of protein. (Louwer) plot (0.90 + 0.07) did not differ significantly from the value of Schild plot for inhibition by cimetidine of histamine-stimulated 1.0 which is predicted by assuming simple competitive kinetics. adenylate cyclase activity in the guinea pig hippocampus. Ten de- The pA2 value was 6.22 + 0.03. The pA2 value for cimetidine terminations were made on four preparations with histamine as the agonist, and two determinations on one preparation with dimaprit on dimaprit-stimulated adenylate cyclase activity in two as agonist. The dose ratios were calculated as the ratio of the ED5o of was preparations of membranes of the guinea pig neocortex the agonist in the presence of cimetidine to the ED50 in the absence similar, 6.45 + 0.19. These are very close (Table 2) to the pA2 of cimetidine. The line has unit slope and an x-intercept (pA2 value) values obtained (16-18) on other H2-receptors. Other H2-an- of 6.22. tagonists caused a parallel shift in the dose-response curves.
Load more

Recommended publications
  • Medicines Regulations 1984 (SR 1984/143)
    Reprint as at 1 July 2014 Medicines Regulations 1984 (SR 1984/143) David Beattie, Governor-General Order in Council At the Government House at Wellington this 5th day of June 1984 Present: His Excellency the Governor-General in Council Pursuant to section 105 of the Medicines Act 1981, and, in the case of Part 3 of the regulations, to section 62 of that Act, His Excellency the Governor-General, acting on the advice of the Minister of Health tendered after consultation with the organisations and bodies that ap- peared to the Minister to be representatives of persons likely to be substantially affected, and by and with the advice and consent of the Executive Council, hereby makes the following regulations. Contents Page 1 Title and commencement 5 Note Changes authorised by subpart 2 of Part 2 of the Legislation Act 2012 have been made in this official reprint. Note 4 at the end of this reprint provides a list of the amendments incorporated. These regulations are administered by the Ministry of Health. 1 Reprinted as at Medicines Regulations 1984 1 July 2014 2 Interpretation 5 Part 1 Classification of medicines 3 Classification of medicines 11 Part 2 Standards 4 Standards for medicines, related products, medical 11 devices, cosmetics, and surgical dressings 5 Pharmacist may dilute medicine in particular case 12 6 Colouring substances [Revoked] 12 Part 3 Advertisements 7 Advertisements not to claim official approval 13 8 Advertisements for medicines 13 9 Advertisements for related products 15 10 Advertisements for medical devices 15 11 Advertisements
    [Show full text]
  • Glucocorticoids with Ketamine and Pentobarbitone- Induced General Anaesthesia in the Rat: Possible Effects on Central Cholinergic Activity
    Br. J. Pharmac. (1984), 82,339-347 Interactions of cholinesterase inhibitors and glucocorticoids with ketamine and pentobarbitone- induced general anaesthesia in the rat: possible effects on central cholinergic activity Remy S. Leeuwin, Jan K. van der Wal & Willem Spanjer Pharmacological Laboratory, University of Amsterdam, Polderweg 104,1093 KP Amsterdam, The Netherlands 1 Doses of 100, 150 and 200 igkg-1 of the cholinesterase inhibitor neostigmine reverse the anaesthetic action of ketamine. The antagonistic effect is increased as the dose is increased. The duration of anaesthesia induced by pentobarbitone is reversed by the cholinesterase inhibitor in doses of 150, 200 and 250 tig kg-1. 2 Choline, in a dose of 50mg kg-, significantly antagonizes the action of the two anaesthetics, whereas hemicholinium-3, an inhibitor of the uptake of choline and the synthesis of acetylcholine, markedly potentiates their action. 3 Dexamethasone induces a significant reduction of the duration of anaesthesia produced by ketamine and pentobarbitone. The potentiation of the anaesthetic effect caused by hemicholinium-3 is also reversed by dexamethasone. 4 The acetylcholine content in rat cerebral cortex is increased after treatment with ketamine and pentobarbitone. 5 Measurements of the course of the plasma level of pentobarbitone do not reveal alterations in the pharmacokinetic profile by either neostigmine or dexamethasone. 6 These results indicate that central cholinergic systems may somehow be involved in the anaesthesia induced by ketamine and pentobarbitone and that the interactions described in this paper may be the result of modification by neostigmine and dexamethasone of the alterations in cholinergic activity caused by the two anaesthetics. Introduction In 1977 Balmer & Wyte showed that physostigmine after completion of the operation was actually pro- antagonized the sedative effects of diazepam and longed.
    [Show full text]
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]
  • Pharmacology and Toxicology of Metiamide, a Histamine H
    9 November 1974 S.-A. MEDIESE TYDSKRIF 2253 Pharmacology and Toxicology of Metiamide, a - Histamine H2 Receptor Antagonist R. W. BRIMBLECOMBE, W. A. M. DUNCAN, M. E. PARSONS SUMMARY x 10-'M on atrial muscle and 7,5 x lO-rM on uterine muscle. Even. at lO-'M, metiamide did not inhibit the A brief review of the pharmacology and toxicology of effects of isoprenaline on either of these tissues neither did it inhibit the effects of histamine on isolated Quinea- metiamide, a histamine H2-receptor antagonist, is given, ~ and evidence is presented to support the view that it pig ileum (mediated through H,-receptors). inhibits gastric acid secretion by virtue of its Hrreceptor Metiamide is also an inhibitor of gastric acid secretion. antagonist activity. Its effectiveness was estimated in two preparations: the Studies are also reported which show that metiamide lumen-perfused stomach of the anaesthetised rat' and given either intravenously or intraduodenally inhibits his­ the conscious Heidenhain pouch dog, prepared 1 - 3 years tamine- or pentagastrin-stimulated acid secretion in human before experimentation. Metiamide was given by rapid subjects. llltravenous injection during a maximal plateau of acid secretion stimulated by either histamine or pentagastrin, and the dose required to reduce this level of secretion by S. Afr. Med. J., 48, 2253 (1974). 50% (ED",) was estimated. The results are shown in Table I and indicate that the ED", values are very similar Conventional antihistaminic drugs, such as mepyramine. even in high concentrations, fail to inhibit histamine­ against those of both histamine and pentagastrin. Doses of stimulated gastric acid secretion.
    [Show full text]
  • United States Patent (19) (11) 4,310,524 Wiech Et Al
    United States Patent (19) (11) 4,310,524 Wiech et al. 45 Jan. 12, 1982 (54) TCA COMPOSITION AND METHOD FOR McMillen et al., Fed. Proc., 38,592 (1979). RAPD ONSET ANTDEPRESSANT Sellinger et al., Fed. Proc., 38,592 (1979). THERAPY Pandey et al., Fed. Proc., 38,592 (1979). 75) Inventors: Norbert L. Wiech; Richard C. Ursillo, Primary Examiner-Stanley J. Friedman both of Cincinnati, Ohio Attorney, Agent, or Firm-Millen & White 73) Assignee: Richardson-Merrell, Inc., Wilton, Conn. (57 ABSTRACT A method is provided for treating depression in a pa (21) Appl. No.: 139,498 tient therefrom and requiring rapid symptomatic relief, (22 Filed: Apr. 11, 1980 which comprises administering to said patient concur 51) Int. Cl. .................... A61K 31/33; A61K 31/135 rently (a) an effective antidepressant amount of a tricy clic antidepressant or a pharmaceutically effective acid (52) ...... 424/244; 424/330 addition salt thereof, and (b) an amount of an a-adrener 58) Field of Search ................................ 424/244, 330 gic receptor blocking agent effective to achieve rapid (56) References Cited onset of the antidepressant action of (a), whereby the PUBLICATIONS onset of said antidepressant action is achieved within Chemical Abst., vol. 66-72828m, (1967), Kellett. from 1 to 7 days. Chemical Abst, vol. 68-94371a, (1968), Martelli et al. A pharmaceutical composition is also provided which is Chemical Abst., vol. 74-86.048j, (1971), Dixit et al. especially adapted for use with the foregoing method. Holmberg et al., Psychopharm., 2,93 (1961). Svensson, Symp. Med. Hoechst., 13, 245 (1978). 17 Claims, No Drawings 4,310,524 1.
    [Show full text]
  • 4 Supplementary File
    Supplemental Material for High-throughput screening discovers anti-fibrotic properties of Haloperidol by hindering myofibroblast activation Michael Rehman1, Simone Vodret1, Luca Braga2, Corrado Guarnaccia3, Fulvio Celsi4, Giulia Rossetti5, Valentina Martinelli2, Tiziana Battini1, Carlin Long2, Kristina Vukusic1, Tea Kocijan1, Chiara Collesi2,6, Nadja Ring1, Natasa Skoko3, Mauro Giacca2,6, Giannino Del Sal7,8, Marco Confalonieri6, Marcello Raspa9, Alessandro Marcello10, Michael P. Myers11, Sergio Crovella3, Paolo Carloni5, Serena Zacchigna1,6 1Cardiovascular Biology, 2Molecular Medicine, 3Biotechnology Development, 10Molecular Virology, and 11Protein Networks Laboratories, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 34149, Trieste, Italy 4Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy 5Computational Biomedicine Section, Institute of Advanced Simulation IAS-5 and Institute of Neuroscience and Medicine INM-9, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany 6Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy 7National Laboratory CIB, Area Science Park Padriciano, Trieste, 34149, Italy 8Department of Life Sciences, University of Trieste, Trieste, 34127, Italy 9Consiglio Nazionale delle Ricerche (IBCN), CNR-Campus International Development (EMMA- INFRAFRONTIER-IMPC), Rome, Italy This PDF file includes: Supplementary Methods Supplementary References Supplementary Figures with legends 1 – 18 Supplementary Tables with legends 1 – 5 Supplementary Movie legends 1, 2 Supplementary Methods Cell culture Primary murine fibroblasts were isolated from skin, lung, kidney and hearts of adult CD1, C57BL/6 or aSMA-RFP/COLL-EGFP mice (1) by mechanical and enzymatic tissue digestion. Briefly, tissue was chopped in small chunks that were digested using a mixture of enzymes (Miltenyi Biotec, 130- 098-305) for 1 hour at 37°C with mechanical dissociation followed by filtration through a 70 µm cell strainer and centrifugation.
    [Show full text]
  • Involvement of Sigma-1 Receptors in the Antidepressant-Like Effects of Dextromethorphan
    Involvement of Sigma-1 Receptors in the Antidepressant-like Effects of Dextromethorphan Linda Nguyen, Matthew J. Robson¤, Jason R. Healy, Anna L. Scandinaro, Rae R. Matsumoto* Department of Basic Pharmaceutical Sciences, and Department of Behavioral Medicine and Psychiatry, West Virginia University, Morgantown, West Virginia, United States of America Abstract Dextromethorphan is an antitussive with a high margin of safety that has been hypothesized to display rapid-acting antidepressant activity based on pharmacodynamic similarities to the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine. In addition to binding to NMDA receptors, dextromethorphan binds to sigma-1 (s1) receptors, which are believed to be protein targets for a potential new class of antidepressant medications. The purpose of this study was to determine whether dextromethorphan elicits antidepressant-like effects and the involvement of s1 receptors in mediating its antidepressant-like actions. The antidepressant-like effects of dextromethorphan were assessed in male, Swiss Webster mice using the forced swim test. Next, s1 receptor antagonists (BD1063 and BD1047) were evaluated in conjunction with dextromethorphan to determine the involvement of s receptors in its antidepressant-like effects. Quinidine, a cytochrome P450 (CYP) 2D6 inhibitor, was also evaluated in conjunction with dextromethorphan to increase the bioavailability of dextromethorphan and reduce exposure to additional metabolites. Finally, saturation binding assays were performed to assess the manner in which dextromethorphan interacts at the s1 receptor. Our results revealed dextromethorphan displays antidepressant-like effects in the forced swim test that can be attenuated by pretreatment with s1 receptor antagonists, with BD1063 causing a shift to the right in the dextromethorphan dose response curve.
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • 5994392 Tion of Application No. 67375.734 Eb3-1685, PEN. T
    USOO5994392A United States Patent (19) 11 Patent Number: 5,994,392 Shashoua (45) Date of Patent: Nov.30, 1999 54 ANTIPSYCHOTIC PRODRUGS COMPRISING 5,120,760 6/1992 Horrobin ................................. 514/458 AN ANTIPSYCHOTICAGENT COUPLED TO 5,141,958 8/1992 Crozier-Willi et al. ................ 514/558 AN UNSATURATED FATTY ACID 5,216,023 6/1993 Literati et al. .......................... 514/538 5,246,726 9/1993 Horrobin et al. ....................... 424/646 5,516,800 5/1996 Horrobin et al. ....................... 514/560 75 Inventor: Victor E. Shashoua, Brookline, Mass. 5,580,556 12/1996 Horrobin ................................ 424/85.4 73 Assignee: Neuromedica, Inc., Conshohocken, Pa. FOREIGN PATENT DOCUMENTS 30009 6/1981 European Pat. Off.. 21 Appl. No.: 08/462,820 009 1694 10/1983 European Pat. Off.. 22 Filed: Jun. 5, 1995 09 1694 10/1983 European Pat. Off.. 91694 10/1983 European Pat. Off.. Related U.S. Application Data 59-025327 2/1984 Japan. 1153629 6/1989 Japan. 63 Continuation of application No. 08/080,675, Jun. 21, 1993, 1203331 8/1989 Japan. abandoned, which is a continuation of application No. 07/952,191, Sep. 28, 1992, abandoned, which is a continu- (List continued on next page.) ation of application No. 07/577,329, Sep. 4, 1990, aban doned, which is a continuation-in-part of application No. OTHER PUBLICATIONS 07/535,812,tion of application Jun. 11, No. 1990, 67,375.734 abandoned, Eb3-1685, which is a continu-PEN. T. Higuchi et al. 66 Prodrugs as Noye Drug Delivery Sys 4,933,324, which is a continuation-in-part of application No.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,773,457 Nahoum (45) Date of Patent: Jun
    USOO5773457A United States Patent (19) 11 Patent Number: 5,773,457 Nahoum (45) Date of Patent: Jun. 30, 1998 54) COMPOSITIONS 4,863,911 9/1989 Anderson et al.. 4,931,445 6/1990 Goldstein et al.. 75 Inventor: Cesar Roberto Dias Nahoum, 5,059.603 10/1991 Rubin. SmithKline Beechman Corporation 5,145,852 9/1992 Virag. Corporate Intellectual Property, 5,147,855 9/1992 Gozes et al.. 5,177,070 1/1993 Katz. UW2220 P.O. Box 1539, King of 5.190,9672----- Y-2 3/1993 Riley. Prussia, Pa. 19406-0939 5,192,806 3/1993 Pill et al.. 5,214,030 5/1993 Stief. 73 Assignee: Cesar Roberto Dias Nahoum, Rio de 5.242,391 9/1993 Place et al.. Janeiro, Brazil 5,256,652 10/1993 El-Rashidy. 5,270,323 12/1993 Milne et al.. 21 Appl. No.: 444,130 5,336,678 8/1994 Cavallini. 9 5,474,535 12/1995 Place et al.. 22 Filled: Mayy 18,18, 1995 5,565,466 10/1996 Gioco et al. ............................ 514/400 Related U.S. Application Data FOREIGN PATENT DOCUMENTS 0 266968 A2 5/1988 European Pat. Off.. 63 Continuation of Ser. No. 381,945, Feb. 15, 1995. O 432 199 B1 9/1989 European Pat. Off.. 6 O 346 297 A1 12/1989 European Pat. Off.. 51) Int. Cl. ................................................... A61K 31/415 0.357 581 A1 3/1990 European Pat. Off.. 52 U.S. Cl. ............................................. 514/397; 514/400 0.357581. B1 3/1990 European Pat. Off.. 58 Field of Search ..................................... 514/400, 397, O 459377 A2 12/1991 European Pat.
    [Show full text]
  • International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors
    1521-0081/67/3/601–655$25.00 http://dx.doi.org/10.1124/pr.114.010249 PHARMACOLOGICAL REVIEWS Pharmacol Rev 67:601–655, July 2015 Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics ASSOCIATE EDITOR: ELIOT H. OHLSTEIN International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors Pertti Panula, Paul L. Chazot, Marlon Cowart, Ralf Gutzmer, Rob Leurs, Wai L. S. Liu, Holger Stark, Robin L. Thurmond, and Helmut L. Haas Department of Anatomy, and Neuroscience Center, University of Helsinki, Finland (P.P.); School of Biological and Biomedical Sciences, University of Durham, United Kingdom (P.L.C.); AbbVie, Inc. North Chicago, Illinois (M.C.); Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany (R.G.); Department of Medicinal Chemistry, Amsterdam Institute of Molecules, Medicines and Systems, VU University Amsterdam, The Netherlands (R.L.); Ziarco Pharma Limited, Canterbury, United Kingdom (W.L.S.L.); Institute of Pharmaceutical and Medical Chemistry (H.S.) and Institute of Neurophysiology, Medical Faculty (H.L.H.), Heinrich-Heine-University Duesseldorf, Germany; and Janssen Research & Development, LLC, San Diego, California (R.L.T.) Abstract ....................................................................................602 Downloaded from I. Introduction and Historical Perspective .....................................................602 II. Histamine H1 Receptor . ..................................................................604 A. Receptor Structure
    [Show full text]
  • Rat Animal Models for Screening Medications to Treat Alcohol Use Disorders
    ACCEPTED MANUSCRIPT Selectively Bred Rats Page 1 of 75 Rat Animal Models for Screening Medications to Treat Alcohol Use Disorders Richard L. Bell*1, Sheketha R. Hauser1, Tiebing Liang2, Youssef Sari3, Antoinette Maldonado-Devincci4, and Zachary A. Rodd1 1Indiana University School of Medicine, Department of Psychiatry, Indianapolis, IN 46202, USA 2Indiana University School of Medicine, Department of Gastroenterology, Indianapolis, IN 46202, USA 3University of Toledo, Department of Pharmacology, Toledo, OH 43614, USA 4North Carolina A&T University, Department of Psychology, Greensboro, NC 27411, USA *Send correspondence to: Richard L. Bell, Ph.D.; Associate Professor; Department of Psychiatry; Indiana University School of Medicine; Neuroscience Research Building, NB300C; 320 West 15th Street; Indianapolis, IN 46202; e-mail: [email protected] MANUSCRIPT Key Words: alcohol use disorder; alcoholism; genetically predisposed; selectively bred; pharmacotherapy; family history positive; AA; HAD; P; msP; sP; UChB; WHP Chemical compounds studied in this article Ethanol (PubChem CID: 702); Acamprosate (PubChem CID: 71158); Baclofen (PubChem CID: 2284); Ceftriaxone (PubChem CID: 5479530); Fluoxetine (PubChem CID: 3386); Naltrexone (PubChem CID: 5360515); Prazosin (PubChem CID: 4893); Rolipram (PubChem CID: 5092); Topiramate (PubChem CID: 5284627); Varenicline (PubChem CID: 5310966) ACCEPTED _________________________________________________________________________________ This is the author's manuscript of the article published in final edited form as: Bell, R. L., Hauser, S. R., Liang, T., Sari, Y., Maldonado-Devincci, A., & Rodd, Z. A. (2017). Rat animal models for screening medications to treat alcohol use disorders. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2017.02.004 ACCEPTED MANUSCRIPT Selectively Bred Rats Page 2 of 75 The purpose of this review is to present animal research models that can be used to screen and/or repurpose medications for the treatment of alcohol abuse and dependence.
    [Show full text]